![Michel Pairet](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michel Pairet
Directeur Général chez
Boehringer Ingelheim Corporate Center GmbH
Profil
Michel Pairet currently works at Boehringer Ingelheim RCV GmbH & Co. KG, as Director, Boehringer Ingelheim Corporate Center GmbH, as Co-Managing Director, C.H.
Boehringer Sohn AG & Co. KG, as Member -Management Board, and Boehringer Ingelheim International GmbH, as Member-Management Board.
Dr. Pairet also formerly worked at Eyevensys SAS, as Director, Okairos AG, as Director, and Boehringer Ingelheim (Venture Capital), as Head from 2014 to 2016.
Postes actifs de Michel Pairet
| Sociétés | Poste | Début |
|---|---|---|
Boehringer Ingelheim RCV GmbH & Co. KG
 Boehringer Ingelheim RCV GmbH & Co. KG BiotechnologyHealth Technology Develops and supplies biotherapeutic proteins, plasmid DNA and antibody fragments | Directeur/Membre du Conseil | - |
Boehringer Ingelheim International GmbH
 Boehringer Ingelheim International GmbH Pharmaceuticals: MajorHealth Technology Engages in development, manufacturing and marketing of medicines for humans & animals | Corporate Officer/Principal | 01/01/1997 |
C.H. Boehringer Sohn AG & Co. KG
 C.H. Boehringer Sohn AG & Co. KG Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops immuno-oncology therapies and veterinary drugs | Corporate Officer/Principal | - |
Boehringer Ingelheim Corporate Center GmbH
 Boehringer Ingelheim Corporate Center GmbH Real Estate DevelopmentFinance Leases real estate properties | Directeur Général | - |
Anciens postes connus de Michel Pairet
| Sociétés | Poste | Fin |
|---|---|---|
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm focuses on companies operating in groundbreaking innovation including cancer, auto-immunity indications, digital solutions, infectious disease and regenerative medicine services. It provides financing for seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes board seat. | President | 01/01/2016 |
Okairos AG
 Okairos AG Pharmaceuticals: MajorHealth Technology Discovers and develops preventive and therapeutic vaccines against human chronic infectious diseases | Directeur/Membre du Conseil | - |
Eyevensys SAS
 Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Develops non-viral gene therapy process for the treatment of ocular illnesses | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
27
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
C.H. Boehringer Sohn AG & Co. KG
C.H. Boehringer Sohn AG & Co. KG Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops immuno-oncology therapies and veterinary drugs | Health Technology |
Okairos AG
Okairos AG Pharmaceuticals: MajorHealth Technology Discovers and develops preventive and therapeutic vaccines against human chronic infectious diseases | Health Technology |
Boehringer Ingelheim RCV GmbH & Co. KG
Boehringer Ingelheim RCV GmbH & Co. KG BiotechnologyHealth Technology Develops and supplies biotherapeutic proteins, plasmid DNA and antibody fragments | Health Technology |
Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH Pharmaceuticals: MajorHealth Technology Engages in development, manufacturing and marketing of medicines for humans & animals | Health Technology |
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm focuses on companies operating in groundbreaking innovation including cancer, auto-immunity indications, digital solutions, infectious disease and regenerative medicine services. It provides financing for seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes board seat. | Finance |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Develops non-viral gene therapy process for the treatment of ocular illnesses | Commercial Services |
Boehringer Ingelheim Corporate Center GmbH
Boehringer Ingelheim Corporate Center GmbH Real Estate DevelopmentFinance Leases real estate properties | Finance |
